154 related articles for article (PubMed ID: 21641287)
1. [Direct health care costs in patients with type 2 diabetes mellitus six months after starting insulin treatment in Spain: the INSTIGATE study].
Costi M; Smith H; Reviriego J; Castell C; Goday A; Dilla T
Endocrinol Nutr; 2011; 58(6):274-82. PubMed ID: 21641287
[TBL] [Abstract][Full Text] [Related]
2. Direct healthcare costs and clinical outcomes after insulin initiation in patients with type 2 diabetes mellitus in Spain: 24-month follow-up data from the INSTIGATE study.
Dilla T; Nicolay C; Alvarez M; Reviriego J; Goday A; Castell C
Endocrinol Nutr; 2013 May; 60(5):224-34. PubMed ID: 23528647
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of insulin initiation on resource utilization and direct costs of treatment over 12 months in patients with type 2 diabetes in Europe: results from INSTIGATE and TREAT observational studies.
Brismar K; Benroubi M; Nicolay C; Schmitt H; Giaconia J; Reaney M
J Med Econ; 2013 Aug; 16(8):1022-35. PubMed ID: 23738910
[TBL] [Abstract][Full Text] [Related]
4. Economic Impact of Treatment Duration and Persistence with Basal Insulin in Previously Insulin-Naive Users.
Kalirai S; Duan R; Liu D; Reed BL
J Manag Care Spec Pharm; 2017 Mar; 23(3):327-336. PubMed ID: 28230446
[TBL] [Abstract][Full Text] [Related]
5. The evaluation of clinical and cost outcomes associated with earlier initiation of insulin in patients with type 2 diabetes mellitus.
Smolen HJ; Murphy DR; Gahn JC; Yu X; Curtis BH
J Manag Care Spec Pharm; 2014 Sep; 20(9):968-84. PubMed ID: 25166296
[TBL] [Abstract][Full Text] [Related]
6. Use of healthcare resources and costs associated to the start of treatment with injectable drugs in patients with type 2 diabetes mellitus.
Sicras-Mainar A; Navarro-Artieda R; Morano R; Ruíz L
Endocrinol Nutr; 2016 Dec; 63(10):527-535. PubMed ID: 27744013
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes and costs for patients with type 2 diabetes mellitus initiating insulin therapy in Greece: two-year experience from the INSTIGATE study.
Aloumanis K; Benroubi M; Sourmeli S; Drossinos V
Prim Care Diabetes; 2013 Oct; 7(3):235-42. PubMed ID: 23623608
[TBL] [Abstract][Full Text] [Related]
8. Clinical and Economic Outcomes of Patients with Type 2 Diabetes on Multiple Daily Injections of Basal-bolus Insulin (MDI) Therapy: A Retrospective Cohort Study.
Brixner D; Ermakova A; Xiong Y; Sieradzan R; Sacks N; Cyr P; Taylor SD
Clin Ther; 2019 Feb; 41(2):303-313.e1. PubMed ID: 30709610
[TBL] [Abstract][Full Text] [Related]
9. [Costs of therapy of insulin-treated patients with Diabetes mellitus in Germany. Results of the JEVIN trial].
Schiel R; Müller UA; Stein G
Med Klin (Munich); 2005 Aug; 100(8):453-61. PubMed ID: 16096726
[TBL] [Abstract][Full Text] [Related]
10. Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population.
Kalsekar I; Iyer S; Mody R; Rajagopalan R; Kavookjian J
J Manag Care Pharm; 2006 Mar; 12(2):121-9. PubMed ID: 16515370
[TBL] [Abstract][Full Text] [Related]
11. A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes.
Borah BJ; Darkow T; Bouchard J; Aagren M; Forma F; Alemayehu B
Clin Ther; 2009 Mar; 31(3):623-31. PubMed ID: 19393853
[TBL] [Abstract][Full Text] [Related]
12. Resource utilization and costs associated with using insulin therapy within a newly diagnosed type 2 diabetes mellitus population.
Bell K; Parasuraman S; Raju A; Shah M; Graham J; Denno M
J Manag Care Spec Pharm; 2015 Mar; 21(3):220-8a. PubMed ID: 25726031
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada.
Tunis SL; Sauriol L; Minshall ME
Appl Health Econ Health Policy; 2010; 8(4):267-80. PubMed ID: 20578781
[TBL] [Abstract][Full Text] [Related]
14. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
15. [Costs of diabetes care and treatment satisfaction in type 2 diabetes patients treated with a basal-bolus (ICT) insulin regimen in outpatient care: results of the LIVE-COM study].
Bierwirth RA; Kohlmann T; Moock J; Holle R; Landgraf W
Med Klin (Munich); 2010 Nov; 105(11):792-801. PubMed ID: 21136237
[TBL] [Abstract][Full Text] [Related]
16. Study of direct costs of type 1 diabetes mellitus in Andalusian patients aged 2-16 years.
Álvarez Casaño M; Alonso Montejo MDM; Leiva Gea I; Jiménez Hinojosa JM; Santos Mata MÁ; Macías F; Romero Pérez MDM; de Toro M; Martínez G; Munguira P; Vivas G; López Siguero JP
Endocrinol Diabetes Nutr (Engl Ed); 2019 Oct; 66(8):480-486. PubMed ID: 31122889
[TBL] [Abstract][Full Text] [Related]
17. Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis.
Gaebler JA; Soto-Campos G; Alperin P; Cohen M; Blickensderfer A; Wintle M; Maggs D; Hoogwerf B; Han J; Pencek R; Peskin B
Vasc Health Risk Manag; 2012; 8():255-64. PubMed ID: 22566747
[TBL] [Abstract][Full Text] [Related]
18. Basal insulin persistence, associated factors, and outcomes after treatment initiation among people with type 2 diabetes mellitus in the US.
Perez-Nieves M; Kabul S; Desai U; Ivanova JI; Kirson NY; Cummings AK; Birnbaum HG; Duan R; Cao D; Hadjiyianni I
Curr Med Res Opin; 2016; 32(4):669-80. PubMed ID: 26703951
[TBL] [Abstract][Full Text] [Related]
19. Glycemic control with insulin glargine plus insulin glulisine versus premixed insulin analogues in real-world practices: a cost-effectiveness study with a randomized pragmatic trial design.
Levin PA; Zhang Q; Mersey JH; Lee FY; Bromberger LA; Bhushan M; Bhushan R
Clin Ther; 2011 Jul; 33(7):841-50. PubMed ID: 21719107
[TBL] [Abstract][Full Text] [Related]
20. Direct health care costs of diabetic patients in Spain.
Oliva J; Lobo F; Molina B; Monereo S
Diabetes Care; 2004 Nov; 27(11):2616-21. PubMed ID: 15504995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
